The stock has been given an average rating of “Hold” by the six investment firms following Bioventus Inc. (NYSE: BCS), as reported by Bloomberg.com. One of the equity research analysts has rated the stock as a sell; four of the analysts have recommended that investors maintain their current positions; and one of the analysts has recommended that investors purchase the stock. According to their average price estimate, brokers who have reported on the stock in the preceding year have assigned a price target of $8.80 for the next 12 months.
Recent reports on BVS have been produced and distributed by many research institutions. In a report distributed on November 9th, Canaccord Genuity Group lowered their price objective for Bioventus from $18.00 to $6.00 and downgraded the company from a “buy” rating to a “hold” rating. In a report distributed on November 9th, Canaccord Genuity Group lowered their price objective for Bioventus from $18.00 to $6.00 and downgraded the company from a “buy” rating to a “hold” rating. In a research report that was made public on November 9th, JPMorgan Chase & Co. announced that they would be switching their stance on the shares of Bioventus from “overweight” to “underweight.” In a research report published on November 10th, Morgan Stanley lowered their price objective for Bioventus shares from $11.00 down to $5.00 and downgraded their “overweight” rating that they had previously assigned to the company’s stock. Finally, but certainly not least, Craig Hallum shifted his recommendation on Bioventus shares from “buy” to “hold” and set his target price for the company at $10.00. Additionally, he established a target price of $10.00 for the stock. On November 22nd, which was a Tuesday, a report was made available to the public.
Recent transactions by institutional investors have resulted in changes to the proportion of the company’s stock held by these investors. During the second quarter, Strs Ohio increased the amount of Bioventus stock owned by 6.0%, bringing the total to 100%. Strs Ohio now has a total of 28,100 shares in the company, valued at $191,000 after purchasing an additional 1,600 shares during the period in question. Lazard Asset Management LLC increased the number of Bioventus shares in its portfolio by 123.9% in the first three months of this year. Lazard Asset Management LLC now has a total of 3,132 shares of the company’s stock, worth $44,000, after purchasing an additional 1,733 shares during the period in question. These shares were purchased during the period in question. Through the first three months of 2018, HighTower Advisors LLC was able to amass an additional 15.5% of the total number of shares of Bioventus common stock. HighTower Advisors LLC now has 14,965 shares of the company’s stock, valued at $211,000, after making an additional purchase of 2,007 shares during the period in question. PNC Financial Services Group Inc. increased the amount of Bioventus stock owned by 1,845.5% over the year’s first three months. After making an additional purchase of 2,030 shares during the most recent period, PNC Financial Services Group Inc. now has a total of 2,140 shares of the company’s stock, which are worth a combined total of $30,000. This brings the company’s overall holdings to 2,140, an increase from the previous total of 2,030 shares.
Last but not least, during the third quarter, SG Americas Securities LLC witnessed a rise in the value of the interests it held in Bioventus, which was 23.1% higher than before. SG Americas Securities LLC now has 16,324 shares of the company’s stock, which has a value of USD 114,000, after purchasing an additional 3,059 shares throughout the most recent period. These shares were acquired through the purchase of additional shares during the most recent period. Currently, 46.88% of the shares in circulation are owned by hedge funds and other institutional investors.
A single share of BVS stock was valued at $2.25 as of the opening bell on Monday. There is currently a value for the quick ratio of 0.67, a value for the current ratio of 0.94, and a value for the debt-to-equity ratio of 1.04. According to a price-to-earnings ratio of -1.09 and a beta of 0.76, the company is worth approximately $174.26 million. The moving averages for the past 50 days come in at $2.44 for the company, and the moving averages for the past 200 days come in at $5.67. Within the last year and a half, the price of Bioventus has ranged from a low of $1.65 to a high of $15.10.
The most recent quarterly earnings report for Bioventus, announced by the company on November 21st and found on the NYSE under the ticker symbol “BVS,” has been made public. Earnings per share for the company came in at $0.05 for the quarter, which was $0.08 less than the consensus estimate of $1.3 among industry experts. Bioventus had a return on equity of 7.87% and a negative net margin of 24.61%. The company also had a negative operating margin. The actual revenue for the quarter was reported to be $128.66 million, which fell short of the market analysts’ expectation of $141.77 million in revenue for the period. During the current fiscal year, industry experts forecast that Bioventus will generate $0.24 per share earnings.
Bioventus, Inc. is a medical device company that focuses on developing and selling therapeutic therapies that collaborate with and improve the body’s natural healing process. These therapies are sold both domestically and internationally. These treatments are marketed both in the domestic and global markets. The company’s product line that specializes in peripheral nerve stimulation includes a wide variety of pain treatment options, such as non-surgical joint pain injection therapy. These are just some of the available pain treatments.
Leave a comment